#CD147

Signal Transduction and Targeted Therapy

@sigtrans-sttt.bsky.social

1 week ago

This study shows #SARSCoV2 upregulates #CD147, driving extended infection and immune imbalance; #Meplazumab blocks CD147–spike interaction, restores immune balance, and mitigates severe #COVID19, highlighting CD147 as a therapeutic target.

#OpenAccess #STTT: doi.org/10.1038/s413...

2 2 1 0

Signal Transduction and Targeted Therapy

@sigtrans-sttt.bsky.social

1 month ago

#SARSCoV2 triggers AHR‑mediated #CD147 up‑regulation, reduces ACE2, and drives immune imbalance through #M2macrophage signaling, while #Meplazumab disrupts CD147‑spike binding, restores immune balance, and mitigates severe #COVID19.

#OpenAccess in #STTT: doi.org/10.1038/s413...

2 1 0 0

LAQV REQUIMTE

@laqv-requimte.bsky.social

3 months ago

📢 #LAQV Webinars
Join us Dec 10, 12h WET!
👉 Lucília Saraiva on beating #hard-to-treat cancer with a first-in-class DDR #inhibitor
👉 Sara Granja on #CD147 & #immunosurveillance
👉 Andreia M. B. da Costa on #pharmacotoxicology of #psychedelics
Chair: Conceição Santos
💻 meet.google.com/kes-ocwa-mfv

0 0 0 0

Signal Transduction and Targeted Therapy

@sigtrans-sttt.bsky.social

5 months ago

Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial - Signal Transduction and Targeted Therapy Signal Transduction and Targeted Therapy - Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial

This phase 3 trial shows that the #humanized #CD147 antibody #meplazumab significantly lowered 14, 28, and 56-day mortality, rapidly reduced #viralload, and improved multiple clinical outcomes in severe #COVID19 patients. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...